Natural Plant Compounds Block Neuropeptide-Triggered Inflammation in Mast Cells

In vitro study using rat peritoneal mast cells. Cells were exposed to neuropeptides (substance P, neurotensin, neuromedin-N) at various concentrations to induce serotonin release. The three lactone compounds were tested as pretreatments and compared against reference anti-allergy drugs (ketotifen and sodium chromoglycate). Serotonin release was measured as the primary outcome of mast cell degranulation.

Neurogenic inflammation — where nerves and immune cells amplify each other's signals — drives conditions like chronic pain, migraines, and irritable bowel syndrome. Current treatments for mast cell activation are limited in effectiveness. Finding natural compounds that specifically block the neuropeptide-mast cell interaction could lead to new therapies for these difficult-to-treat conditions.

This study bridges neuroscience and immunology, addressing the critical neuro-immune crosstalk that underlies many chronic inflammatory and pain conditions. By targeting the specific mechanism by which neuropeptides activate mast cells, these compounds could represent a more precise approach to managing neurogenic inflammation compared to broad anti-inflammatory drugs.

This was an in vitro study using isolated rat mast cells, which may not fully represent the complex in vivo environment of neurogenic inflammation. The compounds were not tested in animal pain models. Human mast cell responses may differ from rat peritoneal mast cells. Pharmacokinetic properties (absorption, metabolism, toxicity) of these lactones were not assessed.